Eyenovia Inc (EYEN) - Total Liabilities
Based on the latest financial reports, Eyenovia Inc (EYEN) has total liabilities worth $15.70 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Eyenovia Inc (EYEN) net asset momentum to track the company's year-over-year net asset growth rate.
Eyenovia Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Eyenovia Inc's total liabilities have evolved over time, based on quarterly financial data. See Eyenovia Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Eyenovia Inc Competitors by Total Liabilities
The table below lists competitors of Eyenovia Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Incheon City G
KO:034590
|
Korea | ₩203.50 Billion |
|
Ekinops SA
PA:EKI
|
France | €88.40 Million |
|
SSF Home Group Berhad
KLSE:0287
|
Malaysia | RM104.38 Million |
|
ZUE SA
WAR:ZUE
|
Poland | zł497.54 Million |
|
Hyundai C&F Inc
KO:227840
|
Korea | ₩71.96 Billion |
|
United U Li Corporation Bhd
KLSE:7133
|
Malaysia | RM46.60 Million |
|
Sab Zenzele Kabili Holdings
JSE:SZK
|
South Africa | ZAC3.48 Billion |
|
Pinar Entegre Et ve Un Sanayi AS
IS:PETUN
|
Turkey | TL5.22 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Eyenovia Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Eyenovia Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eyenovia Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eyenovia Inc (2015–2024)
The table below shows the annual total liabilities of Eyenovia Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $16.76 Million | -15.25% |
| 2023-12-31 | $19.78 Million | +43.32% |
| 2022-12-31 | $13.80 Million | +23.31% |
| 2021-12-31 | $11.19 Million | -39.83% |
| 2020-12-31 | $18.60 Million | +529.11% |
| 2019-12-31 | $2.96 Million | -5.84% |
| 2018-12-31 | $3.14 Million | +468.25% |
| 2017-12-31 | $552.65K | +30.42% |
| 2016-12-31 | $423.73K | +0.93% |
| 2015-12-31 | $419.82K | -- |
About Eyenovia Inc
Eyenovia, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vi… Read more